March 1, 2024 02:33 PM EST
R&D
Pharma
FDA+

GAO di­rects ARPA-H to fi­nal­ize plan for han­dling du­pli­cate re­search

Lia DeGroot

HHS’ newest bio­med­ical re­search arm has yet to fi­nal­ize its char­ter for its ad­vi­so­ry com­mit­tee or ex­plain how mem­bers will put their heads to­geth­er to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times